---
document_datetime: 2025-12-29 11:31:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/orgovyx.html
document_name: orgovyx.html
version: success
processing_time: 0.1001461
conversion_datetime: 2025-12-30 11:48:11.269058
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Orgovyx

[RSS](/en/individual-human-medicine.xml/67557)

##### Authorised

This medicine is authorised for use in the European Union

relugolix Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Orgovyx](#news-on)
- [More information on Orgovyx](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Orgovyx is a medicine used to treat advanced cancer of the prostate (a gland of the male reproductive system) in adult patients when the cancer is 'hormone-sensitive', which means that it responds to treatments that reduce the levels of testosterone (the male sex hormone).

Orgovyx contains the active substance relugolix.

Expand section

Collapse section

## How is Orgovyx used?

Orgovyx is available as tablets. The recommended dose is three tablets on the first day of treatment and then one tablet once a day taken around the same time each day.

The medicine can only be obtained with a prescription. For more information about using Orgovyx, see the package leaflet or contact your doctor or pharmacist.

## How does Orgovyx work?

The testicles produce testosterone which can make prostate cancer cells grow. The active substance in Orgovyx, relugolix, works by blocking a step in the process that signals the testicles to produce testosterone.

This step involves the release of a hormone called gonadotrophin-releasing hormone (GnRH) from the brain. By blocking the effects of GnRH, Orgovyx reduces the amount of testosterone in the body and slows down the growth of the prostate cancer cells.

## What benefits of Orgovyx have been shown in studies?

A main study involving 934 men with advanced hormone-sensitive prostate cancer showed that Orgovyx is effective at reducing the amount of testosterone to levels seen in men whose testicles have been surgically removed.

During the first year, 97% of the patients receiving Orgovyx had the required reduction of testosterone levels, compared with 89% of patients receiving leuprorelin (another medicine for prostate cancer). These results showed that Orgovyx was as effective as leuprorelin.

## What are the risks associated with Orgovyx?

The most common side effects with Orgovyx (which may affect more than 1 in 5 people) are hot flushes, muscle and joint pain and tiredness. Other very common side effects are diarrhoea and constipation.

For the full list of side effects and restrictions for Orgovyx, see the package leaflet.

## Why is Orgovyx authorised in the EU?

The European Medicines Agency decided that Orgovyx's benefits are greater than its risks and it can be authorised for use in the EU.

A main study showed that Orgovyx was as effective as standard treatment with another medicine (leuprorelin) in reducing testosterone levels of patients with advanced hormone-sensitive prostate cancer. Orgovyx was generally well-tolerated by most of the patients. Its side effects were mild and manageable.

## What measures are being taken to ensure the safe and effective use of Orgovyx?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Orgovyx have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Orgovyx are continuously monitored. Suspected side effects reported with Orgovyx are carefully evaluated and any necessary action taken to protect patients.

## Other information about Orgovyx

Orgovyx received a marketing authorisation valid throughout the EU on 29 April 2022.

Orgovyx : EPAR - Medicine Overview

Reference Number: EMA/145519/2022

English (EN) (117.53 KB - PDF)

**First published:** 10/05/2022

[View](/en/documents/overview/orgovyx-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-921)

български (BG) (144.12 KB - PDF)

**First published:**

10/05/2022

[View](/bg/documents/overview/orgovyx-epar-medicine-overview_bg.pdf)

español (ES) (119.63 KB - PDF)

**First published:**

10/05/2022

[View](/es/documents/overview/orgovyx-epar-medicine-overview_es.pdf)

čeština (CS) (140.59 KB - PDF)

**First published:**

10/05/2022

[View](/cs/documents/overview/orgovyx-epar-medicine-overview_cs.pdf)

dansk (DA) (118.71 KB - PDF)

**First published:**

10/05/2022

[View](/da/documents/overview/orgovyx-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.76 KB - PDF)

**First published:**

10/05/2022

[View](/de/documents/overview/orgovyx-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.87 KB - PDF)

**First published:**

10/05/2022

[View](/et/documents/overview/orgovyx-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.87 KB - PDF)

**First published:**

10/05/2022

[View](/el/documents/overview/orgovyx-epar-medicine-overview_el.pdf)

français (FR) (119.83 KB - PDF)

**First published:**

10/05/2022

[View](/fr/documents/overview/orgovyx-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.48 KB - PDF)

**First published:**

10/05/2022

[View](/hr/documents/overview/orgovyx-epar-medicine-overview_hr.pdf)

italiano (IT) (118.93 KB - PDF)

**First published:**

10/05/2022

[View](/it/documents/overview/orgovyx-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.04 KB - PDF)

**First published:**

10/05/2022

[View](/lv/documents/overview/orgovyx-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.98 KB - PDF)

**First published:**

10/05/2022

[View](/lt/documents/overview/orgovyx-epar-medicine-overview_lt.pdf)

magyar (HU) (138.22 KB - PDF)

**First published:**

10/05/2022

[View](/hu/documents/overview/orgovyx-epar-medicine-overview_hu.pdf)

Malti (MT) (142.13 KB - PDF)

**First published:**

10/05/2022

[View](/mt/documents/overview/orgovyx-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.95 KB - PDF)

**First published:**

10/05/2022

[View](/nl/documents/overview/orgovyx-epar-medicine-overview_nl.pdf)

polski (PL) (144.76 KB - PDF)

**First published:**

10/05/2022

[View](/pl/documents/overview/orgovyx-epar-medicine-overview_pl.pdf)

português (PT) (119.91 KB - PDF)

**First published:**

10/05/2022

[View](/pt/documents/overview/orgovyx-epar-medicine-overview_pt.pdf)

română (RO) (139.62 KB - PDF)

**First published:**

10/05/2022

[View](/ro/documents/overview/orgovyx-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.74 KB - PDF)

**First published:**

10/05/2022

[View](/sk/documents/overview/orgovyx-epar-medicine-overview_sk.pdf)

slovenščina (SL) (139.56 KB - PDF)

**First published:**

10/05/2022

[View](/sl/documents/overview/orgovyx-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.81 KB - PDF)

**First published:**

10/05/2022

[View](/fi/documents/overview/orgovyx-epar-medicine-overview_fi.pdf)

svenska (SV) (117.61 KB - PDF)

**First published:**

10/05/2022

[View](/sv/documents/overview/orgovyx-epar-medicine-overview_sv.pdf)

Orgovyx : EPAR - Risk management plan summary

English (EN) (67.15 KB - PDF)

**First published:** 10/05/2022

**Last updated:** 10/06/2022

[View](/en/documents/rmp-summary/orgovyx-epar-risk-management-plan-summary_en.pdf)

## Product information

Orgovyx : EPAR - Product Information

English (EN) (398.62 KB - PDF)

**First published:** 10/05/2022

**Last updated:** 30/09/2025

[View](/en/documents/product-information/orgovyx-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-729)

български (BG) (540.52 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/bg/documents/product-information/orgovyx-epar-product-information_bg.pdf)

español (ES) (539.28 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/es/documents/product-information/orgovyx-epar-product-information_es.pdf)

čeština (CS) (462.94 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/cs/documents/product-information/orgovyx-epar-product-information_cs.pdf)

dansk (DA) (504.41 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/da/documents/product-information/orgovyx-epar-product-information_da.pdf)

Deutsch (DE) (486.29 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/de/documents/product-information/orgovyx-epar-product-information_de.pdf)

eesti keel (ET) (555.91 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/et/documents/product-information/orgovyx-epar-product-information_et.pdf)

ελληνικά (EL) (609.32 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/el/documents/product-information/orgovyx-epar-product-information_el.pdf)

français (FR) (529.2 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/fr/documents/product-information/orgovyx-epar-product-information_fr.pdf)

hrvatski (HR) (482.91 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/hr/documents/product-information/orgovyx-epar-product-information_hr.pdf)

íslenska (IS) (580.06 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/is/documents/product-information/orgovyx-epar-product-information_is.pdf)

italiano (IT) (523.95 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/it/documents/product-information/orgovyx-epar-product-information_it.pdf)

latviešu valoda (LV) (600.06 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/lv/documents/product-information/orgovyx-epar-product-information_lv.pdf)

lietuvių kalba (LT) (537.57 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/lt/documents/product-information/orgovyx-epar-product-information_lt.pdf)

magyar (HU) (571.02 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/hu/documents/product-information/orgovyx-epar-product-information_hu.pdf)

Malti (MT) (648.99 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/mt/documents/product-information/orgovyx-epar-product-information_mt.pdf)

Nederlands (NL) (578.51 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/nl/documents/product-information/orgovyx-epar-product-information_nl.pdf)

norsk (NO) (485.06 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/no/documents/product-information/orgovyx-epar-product-information_no.pdf)

polski (PL) (553.09 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/pl/documents/product-information/orgovyx-epar-product-information_pl.pdf)

português (PT) (478.44 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/pt/documents/product-information/orgovyx-epar-product-information_pt.pdf)

română (RO) (562.12 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/ro/documents/product-information/orgovyx-epar-product-information_ro.pdf)

slovenčina (SK) (533.08 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/sk/documents/product-information/orgovyx-epar-product-information_sk.pdf)

slovenščina (SL) (546.32 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/sl/documents/product-information/orgovyx-epar-product-information_sl.pdf)

Suomi (FI) (500.25 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/fi/documents/product-information/orgovyx-epar-product-information_fi.pdf)

svenska (SV) (501.3 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/sv/documents/product-information/orgovyx-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000295448 29/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Orgovyx : EPAR - All authorised presentations

English (EN) (25.25 KB - PDF)

**First published:** 10/05/2022

**Last updated:** 30/09/2025

[View](/en/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-955)

български (BG) (65.84 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/bg/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.38 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/es/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_es.pdf)

čeština (CS) (63.13 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/cs/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.13 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/da/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (45.02 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/de/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (41.54 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/et/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.87 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/el/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_el.pdf)

français (FR) (42.48 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/fr/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (41.64 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/hr/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.77 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/is/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.48 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/it/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.32 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/lv/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.07 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/lt/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.6 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/hu/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.74 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/mt/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.51 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/nl/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (25.21 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/no/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_no.pdf)

polski (PL) (63.08 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/pl/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_pl.pdf)

português (PT) (41.42 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/pt/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.38 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/ro/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (63.49 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/sk/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.41 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/sl/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.3 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/fi/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25 KB - PDF)

**First published:**

10/05/2022

**Last updated:**

30/09/2025

[View](/sv/documents/all-authorised-presentations/orgovyx-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Orgovyx Active substance relugolix International non-proprietary name (INN) or common name relugolix Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L02BX

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

## Authorisation details

EMA product number EMEA/H/C/005353

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 24/02/2022 Marketing authorisation issued 29/04/2022 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Orgovyx : EPAR - Procedural steps taken and scientific information after information

English (EN) (162.57 KB - PDF)

**First published:** 24/06/2025

**Last updated:** 30/09/2025

[View](/en/documents/procedural-steps-after/orgovyx-epar-procedural-steps-taken-scientific-information-after-information_en.pdf)

Orgovyx : EPAR - Procedural steps taken and scientific information after information (archive)

English (EN) (168.38 KB - PDF)

**First published:** 10/06/2022

**Last updated:** 24/06/2025

[View](/en/documents/procedural-steps-after/orgovyx-epar-procedural-steps-taken-scientific-information-after-information-archive_en.pdf)

Orgovyx-H-C-PSUSA-00010994-202301 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/531133/2023

English (EN) (127.38 KB - PDF)

**First published:** 29/11/2023

[View](/en/documents/scientific-conclusion/orgovyx-h-c-psusa-00010994-202301-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Orgovyx : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/218094/2022

English (EN) (3.45 MB - PDF)

**First published:** 10/05/2022

[View](/en/documents/assessment-report/orgovyx-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Orgovyx

Adopted

Reference Number: EMA/111169/2022

English (EN) (133.81 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-orgovyx_en.pdf)

#### News on Orgovyx

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

#### More information on Orgovyx

- [RENAISSANCE - A multi-centre, non-interventional study of RElugolix as aNdrogen-deprivAtion therapy In patientS with advanced hormone-Sensitive prostate cANCEr - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000077)

**This page was last updated on** 30/09/2025

## Share this page

[Back to top](#main-content)